Age-dependent effects on the treatment response of natalizumab in MS patients

Multiple Sclerosis Journal

Volumn 21, Issue 1, 2015, Pages 48-56

  Matell, Henrik ^a   Lycke, Jan ^b   Svenningsson, Anders ^c   Holmén, Carolina ^a   Khademi, Mohsen ^a   Hillert, Jan ^a   Olsson, Tomas ^a   Piehl, Fredrik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

antibodies; biomarker; monoclonals therapeutic use; multiple sclerosis; Natalizumab; product surveillance; prognosis

Indexed keywords

CXCL13 CHEMOKINE; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGE; ARTICLE; ASSESSMENT OF HUMANS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; SYMBOL DIGIT MODALITY TEST; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; COHORT ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SWEDISH CITIZEN; SYMBOL DIGIT MODALITIES TEST; CEREBROSPINAL FLUID; MIDDLE AGED; REGISTER; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; YOUNG ADULT;

EID: 84922843016     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514536085     Document Type: Article

References (21)

1. Compston A and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Confavreux C and Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006; 129 (Pt 3): 606-616.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
5. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256: 405-415.
6. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011; 17: 708-719.
7. Khademi M, Dring AM, Gilthorpe JD, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: A reflection by cerebrospinal fluid biomarkers. PLoS One 2013; 8: e63172.
8. Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler 2007; 13: 52-57.
9. Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: Replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010; 16: 228-237.
10. Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010; 16: 1385-1392.
11. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized doubleblind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
12. Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Clinicopathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406-411.
13. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133 (Pt 7): 1900-1913.
14. Scalfari A, Neuhaus A, Daumer M, et al. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246-1252.
15. Confavreux C and Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129 (Pt 3): 595-605.
16. Lassmann H, van Horssen J and Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
17. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335-343.
18. Teunissen CE and Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552-556.
19. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
20. Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43-50.
21. Kalincik T, Vivek V, Jokubaitis V, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013; 136 (Pt 12): 3609-3617.